CIA
PTCT icon

CSat Investment Advisory’s PTC Therapeutics PTCT Stock Holding History

CSat Investment Advisory’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-193
Closed -$9K – 851
2020
Q3 		$9K Buy
193
+21
+12% +$1.03K ﹤0.01% 1058
2020
Q2 		$9K Buy
+172
New +$8.45K ﹤0.01% 1062

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CSat Investment Advisory's PTCT Position: Q4 2020 in Review

CSat Investment Advisory sold out of PTC Therapeutics (PTCT) in Q4 2020, closing a stake of 193 shares — an estimated $9K sold.

CSat Investment Advisory first reported a position in PTCT in Q2 2020 and held it in 2 quarters. The position peaked at $9K in Q3 2020. 215 funds tracked by Wall St. Rank hold PTCT as of Q4 2020.

  • CSat Investment Advisory reported no remaining PTC Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 193 PTC Therapeutics shares in Q4 2020, an estimated $9K.
  • CSat Investment Advisory first reported a position in PTC Therapeutics in Q2 2020 and held it in 2 quarters.
  • CSat Investment Advisory's PTC Therapeutics position peaked at $9K in Q3 2020.
  • 215 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.